Chemotherapy is administrated intravenously through a Venous Access Device (VAD). Various types of devices are available including cannula, catheters, and implanted ports. The choice of the device depends on the type of therapy a patient is going to have and physical condition of patient. A central venous access device (CVAD) is made of a non-irritant material, such as silicone, which can be left in place for several weeks or months. CVAD can be used to administer fluids and drugs and can also be used to take blood samples. The main sites for central venous access devices are the external and internal jugular, and sub-clavian veins. Other potential access sites include the cephalic vein in the deltopectoral groove, axillary vein, and femoral vein.d
Get Exclusive Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2231
Increasing demand for chemotherapy and rising cancer incidences worldwide is expected to drive the chemotherapy devices market growth
Cancer is a leading cause of death worldwide. According to the World Health Organization (WHO) report, cancer is the second leading cause of death worldwide, and it was responsible for an estimated 9.6 million deaths in 2018. Increasing consumption of tobacco and alcohol, and rising geriatric population base play an important role in surging the cancer incidence rates. According to the Global Burden of Disease 2015 study, tobacco use is the most important risk factor for cancer and is responsible for around 22% of cancer deaths worldwide.
Moreover, with the rising incidence of cancer the demand for its treatment is also increasing eventually driving the chemotherapy devices market growth. According to the National Cancer Institute (NCI), in 2016, an estimated 15.5 million cancer survivors were reported in the U.S. and the number is expected to increase to 20.3 million by 2026.
Chemotherapy devices can cause some level of discomfort to patients. For instance, during insertion of a skin-tunnelled catheter or port, the needle or guide wire can scratch the top of the lung causing an air pocket. Sometimes there may be bruising at the site where the needle went into vein or there might be damage to an artery or nerve.
Increasing incidences of different cancers worldwide is the major factor driving chemotherapy devices market growth. According to the World Health Organization (WHO), 2017, nearly 1 in 6 deaths occur due to cancer globally and around 70% of deaths from cancer occur in low- and middle-income economies. According to Breast Cancer Organization, in 2017, approximately 252,710 new cases of breast cancer were identified in the U.S., of which 63,410 cases were of non-invasive breast cancer.
Moreover, increasing government and private funding coupled with rising disposable income is also projected to drive chemotherapy devices market growth. According to the National Cancer Institute 2016 report, an estimated national expenditures for cancer care in the U.S. in 2017, were US$ 147.3 billion. Costs are likely to increase over the forecast period, as the population ages and cancer prevalence increases. However, not all chemotherapy patient requires a venous access device. For some chemotherapy treatment plans, the inconvenience of implanting and accessing a VAD can outweigh the benefits.
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2231
Key players operating in the global chemotherapy devices market include Advanced Chemotherapy Technologies, Baxter International, Becton, Dickinson, B. Braun, Fresenius Kabi, Halyard Health, ICU Medical, Moog Inc., Micrel Medical, Smiths Group, Terumo Corporation, and Zyno Medical
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154